RNA Interference-based Therapies for the Reduction of Cardiovascular Risk

Natalia Nazarenko; Jiyoung Seo; Sanjana Nagraj; Leonidas Palaiodimos; Damianos G Kokkinidis

doi:10.2174/0118761429264553231204115314

RNA Interference-based Therapies for the Reduction of Cardiovascular Risk

Curr Mol Pharmacol. 2024 Feb 29. doi: 10.2174/0118761429264553231204115314. Online ahead of print.

Authors

Natalia Nazarenko¹, Jiyoung Seo¹, Sanjana Nagraj², Leonidas Palaiodimos¹, Damianos G Kokkinidis³

Affiliations

¹ Jacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Parkway S, The Bronx, NY 10461, USA.
² Division of Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York 10467, USA.
³ Section of Cardiovascular Medicine, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA.

PMID: 38449067
DOI: 10.2174/0118761429264553231204115314

Abstract

Globally, there remains an unwavering increase in the incidence of cvd - from 271 million in 1990 to 523 million in 2019. Among the several modifiable and non-modifiable risk factors of heart disease, dyslipidemia is an important and prevalent risk factor mediated by both genetics and lifestyle factors. Hence, lowering lipid levels, specifically, ldl-c levels (low-density lipoprotein cholesterol), is a key strategy in decreasing the risk of cardiovascular disease. A reduction of 20 mg/dl in ldl-c levels has been found to prevent 2-3 cases of coronary artery disease (cad) for every 1000 individuals. Studies have also found reductions in ldl-c levels to be associated with a mortality benefit. However, ldl-c levels reduction may not eliminate the risk of significant cardiovascular events.

Keywords: ASO; Cardiovascular risk reduction; LDL; Lipid lowering therapy; Lp(a).; RNA interference; siRNA.